Reactive dirty fragments: Implications for tuberculosis drug discovery

Current Opinion in Microbiology

Volumn 21, Issue , 2014, Pages 7-12

  Gopal, Pooja ^a   Dick, Thomas ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIMYCOBACTERIAL AGENT; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN;

CHEMOTHERAPY; DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; REVIEW; TUBERCULOSIS; WHOLE CELL;

EID: 84904917797     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2014.06.015     Document Type: Review

References (58)

1. WHO Global Tuberculosis Report 2013 2013, World Health Organization.
2. Weis S.E., Slocum P.C., Blais F.X., King B., Nunn M., Matney G.B., Gomez E., Foresman B.H. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994, 330:1179-1184.
3. Mitchison D.A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998, 2:10-15.
4. Zumla A., Nahid P., Cole S.T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
5. Stop T.B. An International Roadmap for Tuberculosis Research: Towards a World Free of Tuberculosis 2011, World Health Organization.
6. Dick T., Dartois V., Keller T., Matter A. TB drug discovery from target identification to proof of concept studies. Handbook of Tuberculosis 2008, 139-159. Wiley-VCH. H. Kaufmann, P. van Helden (Eds.).
7. Andries K., Verhasselt P., Guillemont J., Göhlmann H.W.H., Neefs J.-M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
8. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007, 6:29-40.
9. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., Schnappinger D., Wilkinson R.J., Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
10. Lee R.E., Hurdle J.G., Liu J., Bruhn D.F., Matt T., Scherman M.S., Vaddady P.K., Zheng Z., Qi J., Akbergenov R., et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med 2014, 20:152-158.
11. Gopal M., Padayatchi N., Metcalfe J.Z., O'Donnell M.R. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013, 17:1001-1007.
12. Gammon K. Drug discovery: leaving no stone unturned. Nature 2014, 509:S10-S12.
13. Barry E.C. Lessons from seven decades of antituberculosis drug discovery. Curr Top Med Chem 2011, 11:1216-1225.
14. Jackson M., McNeil M.R., Brennan P.J. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis. Future Microbiol 2013, 8:855-875.
15. Dartois V., Leong F.J., Dick T. Tuberculosis drug discovery: issues, gaps and the way forward. Antiparasitic and Antibacterial Drug Discovery 2009, 415-440. Wiley-VCH. P.M. Selzer (Ed.).
16. Mitchison D.A. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000, 4:796-806.
17. Zhang Y., Heym B., Allen B., Young D., Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358:591-593.
18. Rozwarski D.A., Grant G.A., Barton D.H.R., Jacobs W.R., Sacchettini J.C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998, 279:98-102.
19. Argyrou A., Vetting M.W., Aladegbami B., Blanchard J.S. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat Struct Mol Biol 2006, 13:408-413.
20. Mdluli K., Slayden R.A., Zhu Y., Ramaswamy S., Pan X., Mead D., Crane D.D., Musser J.M., Barry C.E. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 1998, 280:1607-1610.
21. Argyrou A., Jin L., Siconilfi-Baez L., Angeletti R.H., Blanchard J.S. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry 2006, 45:13947-13953.
22. Bernardes-Genisson V., Deraeve C., Chollet A., Bernadou J., Pratviel G. Isoniazid: an update on the multiple mechanisms for a singular action. Curr Med Chem 2013, 20:4370-4385.
23. DeBarber A.E., Mdluli K., Bosman M., Bekker L.-G., Barry C.E. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000, 97:9677-9682.
24. Banerjee A., Dubnau E., Quemard A., Balasubramanian V., Um K., Wilson T., Collins D., de Lisle G., Jacobs W. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263:227-230.
25. Chakraborty S., Gruber T., Barry C.E., Boshoff H.I., Rhee K.Y. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 2013, 339:88-91.
26. Zheng J., Rubin E.J., Bifani P., Mathys V., Lim V., Au M., Jang J., Nam J., Dick T., Walker J.R., et al. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem 2013, 288:23447-23456.
27. Kuo M.R., Morbidoni H.R., Alland D., Sneddon S.F., Gourlie B.B., Staveski M.M., Leonard M., Gregory J.S., Janjigian A.D., Yee C., et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J Biol Chem 2003, 278:20851-20859.
28. Willand N., Dirie B., Carette X., Bifani P., Singhal A., Desroses M., Leroux F., Willery E., Mathys V., Deprez-Poulain R., et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 2009, 15:537-544.
29. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 2014, 12:159-167.
30. Sacchettini J.C., Rubin E.J., Freundlich J.S. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol 2008, 6:41-52.
31. Gengenbacher M., Kaufmann S.H.E. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012, 36:514-532.
32. Mitchison D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985, 66:219-225.
33. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996, 2:662-667.
34. Zhang Y., Wade M.M., Scorpio A., Zhang H., Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003, 52:790-795.
35. Zimhony O., Cox J.S., Welch J.T., Vilcheze C., Jacobs W.R. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000, 6:1043-1047.
36. Boshoff H.I., Mizrahi V., Barry C.E. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol 2002, 184:2167-2172.
37. Sayahi H., Zimhony O., Jacobs W.R., Shekhtman A., Welch J.T. Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I. Bioorg Med Chem Lett 2011, 21:4804-4807.
38. Shi W., Zhang X., Jiang X., Yuan H., Lee J.S., Barry C.E., Wang H., Zhang W., Zhang Y. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011, 333:1630-1632.
39. Zhang S., Chen J., Shi W., Liu W., Zhang W., Zhang Y. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect 2013, 2:e34.
40. Scorpio A., Lindholm-Levy P., Heifets L., Gilman R., Siddiqi S., Cynamon M., Zhang Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997, 41:540-543.
41. Malone L., Schurr A., Lindh H., McKenzie D., Kiser J.S., Williams J.H. The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice. Am Rev Tuberc 1952, 65.
42. Solotorovsky M., Gregory F.J., Ironson E.J., Bugie E.J., O'Neill R.C., Pfister K. Pyrazinoic acid amide-an agent active against experimental murine tuberculosis. Exp Biol Med 1952, 79:563-565.
43. Yeager R.L., Munroe W.G.C., Dessau F.I. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952, 65:523-546.
44. McDermott W., Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 1954, 70:748-754.
45. Zhang Y., Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003, 7:6-21.
46. Koller F., Leuthardt F. Nekrose und autolyse beitrag zur kenntnis der dystrophischen verkalkung. Klinische Wochenschrift 1934, 13:1527-1529.
47. Weiss C., Tabachnick J., Cohen H.P. Mechanism of softening of tubercles III. Hydrolysis of protein and nucleic acid during anaerobic autolysis of normal and tuberculous lung tissue in vitro. Arch Pathol Lab Med 1954, 57:179-193.
48. Scott D.E., Coyne A.G., Hudson S.A., Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 2012, 51:4990-5003.
49. Hopkins A.L., Keseru G.M., Leeson P.D., Rees D.C., Reynolds C.H. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov 2014, 13:105-121.
50. East S.P., Silver L.L. Multitarget ligands in antibacterial research: progress and opportunities. Expert Opin Drug Discov 2013, 8:143-156.
51. Kohanski M.A., Dwyer D.J., Collins J.J. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 2010, 8:423-435.
52. Pujol A., Mosca R., Farrés J., Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010, 31:115-123.
53. Ohlson S. Designing transient binding drugs: a new concept for drug discovery. Drug Discov Today 2008, 13:433-439.
54. Brennan P.J., Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995, 64:29-63.
55. Danilchanka O., Pavlenok M., Niederweis M. Role of porins for uptake of antibiotics by Mycobacterium smegmatis. Antimicrob Agents Chemother 2008, 52:3127-3134.
56. Sarathy J., Dartois V., Dick T., Gengenbacher M. Reduced drug uptake in phenotypically resistant nutrient-starved non-replicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013, 57:1648-1653.
57. Botting R.M. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 2010, 62:518-525.
58. Stangel M., Linker R.A. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. Expert Rev Clin Pharmacol 2013, 6:355-362.